Table 1 Characteristics of subjects
pSS | SLE | RA | HC | |
|---|---|---|---|---|
Number of patients | 43 | 20 | 26 | 44 |
Sex, male/female | 1/42 | 1/19 | 5/21 | 7/37 |
Age, median (range) | 60 (26-77) | 35.5 (26-77) | 55 (23-81) | 41 (19-65) |
Disease duration, median (range) | 9 (1-22) | 6 (0.5-31) | 5.5 (0.5-41) | NA |
Positive anti-Ro(SSA) Ab, n (%) | 32 (74) | NA | NA | NA |
Positive anti-La(SSB) Ab, n (%) | 17 (39) | NA | NA | NA |
Focus score ≥ 1, n (%) | 39 (91) | NA | NA | NA |
Extraglandular manifestations, n (%) | 17 (36) | NA | NA | NA |
Positive anti-DNA antibody, n (%) | NA | 16 (84%) | NA | NA |
Positive anti-CCP antibody, n (%) | NA | NA | 23 (88) | NA |
Positive rheumatoid factor, n (%) | NA | NA | 24 (92) | NA |
Malignant hemopathy, n (%) | 5 (12) | 0 (0) | 0 (0) | 0 (0) |
SLEDAI, median (range) | NA | 3 (1-12) | NA | NA |
DAS28, median (range) | NA | NA | 4.8 (1.2-6.3) | NA |
Secondary APLS | 0 | 4 | 0 | NA |
ESR (mm), median (range) | 22 (4-44) | 22 (4-48) | 25 (4-104) | NA |
C-reactive protein (mg/L), median (range) | 1.0 (1-11) | 1.5 (1-11) | 6 (1-106) | NA |
Fibrinogen (g/L), median (range) | 3.2 (2.6-4.5) | 3.4 (2.2-4.8) | 4.4 (2.4-8.6) | 2.9 (1.7-4.5) |
Beta2 microglobulin level (mg/L), median (range) | 2.4 (1.6-5.6) | NA | NA | NA |
Immunosuppressive drug use, n (%) | 7 (16) | 11 (55) | 19 (73) | NA |